MGC Pharmaceuticals Limited Application for Admission to Trading

TIDMMXC

RNS Number : 8386F

MGC Pharmaceuticals Limited

09 November 2022

MGC Pharmaceuticals Ltd.

Compliance Release - Application for Admission to Trading

9 November 2022

ASX, LSE: MXC

MGC Pharmaceuticals Ltd (' MGC Pharma' or ' the Company ') advises that it is applying for the admission to the Financial Conduct Authority's Official List, and to trading on the Main Market of the LSE for 50,200,000 Fully Paid Ordinary Shares (Shares) issued by MGC Pharma, with the Company is seeking admission to trading for these Shares from 8:00am (GMT) on 10 November 2022.

Details of the 50,200,000 Shares for which these applications have been lodged are as follows:

-- 50,000,000 Shares issued to MGC employees to settle salary/wages in lieu of cash settlement

-- 200,000 Shares issued on the exercise of securities granted under the Company's Employee Share Scheme

--Ends--

Authorised for release by the Chairman, for further information please contact:

 
 MGC Pharmaceuticals Ltd                        MGC Pharmaceuticals Ltd 
  Roby Zomer                                     David Lim 
  CEO & Managing Director                        Company Secretary 
  [phone]                                [phone] 
  [e-mail]                              [e-mail] 
 UK Financial and Corporate                     UK Broker 
  Advisor                                        Turner Pope 
  Hannam & Partners                              Andy Thacker 
  Rupert Fane / Nilesh Patel                     [phone] 
  [phone]                               [e-mail] 
  [e-mail] / [e-mail] 
 UK PR Advisors 
  Tavistock 
  Charles Vivian / Tim Pearson 
  [phone] 
  [e-mail] 
 

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ALSMZMGMGLDGZZM

(END) Dow Jones Newswires

November 09, 2022 05:20 ET (10:20 GMT)